247 related articles for article (PubMed ID: 25275600)
21. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
22. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Chen R; Tsai J; Thompson PA; Chen Y; Xiong P; Liu C; Burrows F; Sivina M; Burger JA; Keating MJ; Wierda WG; Plunkett W
Blood Cancer J; 2021 Mar; 11(3):57. PubMed ID: 33714981
[TBL] [Abstract][Full Text] [Related]
23. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
[TBL] [Abstract][Full Text] [Related]
24. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
25. Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival.
Wang YH; Fan L; Wang L; Zhang R; Zou ZJ; Fang C; Zhang LN; Li JY; Xu W
Leuk Lymphoma; 2013 Jun; 54(6):1165-70. PubMed ID: 23039362
[TBL] [Abstract][Full Text] [Related]
26. Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL.
Kaplan D; Meyerson HJ; Li X; Drasny C; Liu F; Costaldi M; Barr P; Lazarus HM
Cytometry B Clin Cytom; 2010 Mar; 78(2):115-22. PubMed ID: 20014315
[TBL] [Abstract][Full Text] [Related]
27. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.
Chen L; Huynh L; Apgar J; Tang L; Rassenti L; Weiss A; Kipps TJ
Blood; 2008 Mar; 111(5):2685-92. PubMed ID: 18048647
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
Gladkikh AA; Potashnikova DM; Tatarskiy V; Yastrebova M; Khamidullina A; Barteneva N; Vorobjev I
Cancer Med; 2017 Dec; 6(12):2984-2997. PubMed ID: 29125235
[TBL] [Abstract][Full Text] [Related]
29. Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70.
Secchiero P; di Iasio MG; Gonelli A; Barbarotto E; Melloni E; Tiribelli M; Chiaruttini C; Zauli G
J Cell Physiol; 2007 Oct; 213(1):229-36. PubMed ID: 17476690
[TBL] [Abstract][Full Text] [Related]
30. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
31. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.
Le Roy C; Deglesne PA; Chevallier N; Beitar T; Eclache V; Quettier M; Boubaya M; Letestu R; Lévy V; Ajchenbaum-Cymbalista F; Varin-Blank N
Blood; 2012 Jul; 120(2):356-65. PubMed ID: 22613791
[TBL] [Abstract][Full Text] [Related]
32. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
33. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
[TBL] [Abstract][Full Text] [Related]
34. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms determining a differential threshold for sensing Src family kinase activity by B and T cell antigen receptors.
Borna S; Fabisik M; Ilievova K; Dvoracek T; Brdicka T
J Biol Chem; 2020 Sep; 295(37):12935-12945. PubMed ID: 32665402
[TBL] [Abstract][Full Text] [Related]
36. ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
Chen J; Sathiaseelan V; Moore A; Tan S; Chilamakuri CSR; Roamio Franklin VN; Shahsavari A; Jakwerth CA; Hake SB; Warren AJ; Mohorianu I; D'Santos C; Ringshausen I
Blood; 2021 Jul; 137(26):3629-3640. PubMed ID: 33619528
[TBL] [Abstract][Full Text] [Related]
37. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.
Vangapandu HV; Havranek O; Ayres ML; Kaipparettu BA; Balakrishnan K; Wierda WG; Keating MJ; Davis RE; Stellrecht CM; Gandhi V
Mol Cancer Res; 2017 Dec; 15(12):1692-1703. PubMed ID: 28835371
[TBL] [Abstract][Full Text] [Related]
38. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
[TBL] [Abstract][Full Text] [Related]
39. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
40. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
